Deutsche Bank raised the firm’s price target on IFF to $100 from $90 and keeps a Buy rating on the shares. With the sale of Pharma Solutions, IFF has taken a major step in reducing its leverage below 3-times, thereby removing the leverage overhang on the shares that has existed since the merger of IFF and DuPont’s Nutrition & Biosciences business in February 2021, the analyst tells investors in a research note. The firm continues to see “substantial upside” in the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IFF:
- International Flavors & Fragrances Divests Pharma Solutions Business
- IFF to sell Pharma Solutions business to Roquette for $2.85B
- IFF cut to Hold at Argus on higher costs, volume slowdown
- IFF downgraded to Hold from Buy at Argus
- Wolfe starts IFF at Underperform, says valuation in line with higher-end product